Aprea Therapeutics (APRE) Share-based Compensation (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Share-based Compensation of $101068.0 for Q1 2026, down 14.81% year-over-year from $118634.0 in Q1 2025, and down 7.3% quarter-over-quarter from $109024.0 in Q4 2025.
Aprea Therapeutics (APRE) Share-based Compensation (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Share-based Compensation for 9 consecutive years, with $101068.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 14.81% year-over-year to $101068.0; the TTM figure through Mar 2026 stood at $460575.0 (down 11.81% YoY), while the FY2025 annual figure was $478141.0, down 2.31% from the prior year.
- Share-based Compensation declined to $101068.0 in Q1 2026 per APRE's latest filing, from $109024.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $68.0 million in Q2 2022 and bottomed at $16244.0 in Q1 2023.
- Historically, Share-based Compensation has averaged $4.8 million across 5 years, with a median of $118634.0 in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 3550.29% — and 2023, when it tumbled 99.6%.
- Aprea Therapeutics' Share-based Compensation stood at $68.0 million in 2022, then slumped by 99.88% to $82861.0 in 2023, then jumped by 52.1% to $126028.0 in 2024, then declined by 13.49% to $109024.0 in 2025, then fell by 7.3% to $101068.0 in 2026.
- Business Quant data shows APRE's Share-based Compensation at $101068.0 in Q1 2026, $109024.0 in Q4 2025, and $113754.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 103,193.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103,193.00 |
| Jun 30, 2026 | 103,193.00 |
| Mar 31, 2026 | 101,068.00 |
| Mar 31, 2026 | 101,068.00 |
| Dec 31, 2025 | 109,024.00 |
| Dec 31, 2025 | 109,024.00 |
| Sep 30, 2025 | 113,754.00 |
| Sep 30, 2025 | 113,754.00 |
| Jun 30, 2025 | 136,729.00 |
| Jun 30, 2025 | 136,729.00 |
| Mar 31, 2025 | 118,634.00 |
| Mar 31, 2025 | 118,634.00 |
| Dec 31, 2024 | 126,028.00 |
| Dec 31, 2024 | 126,028.00 |
| Sep 30, 2024 | 149,090.00 |
| Sep 30, 2024 | 149,090.00 |
| Jun 30, 2024 | 128,488.00 |
| Jun 30, 2024 | 128,488.00 |
| Mar 31, 2024 | 85,830.00 |
| Mar 31, 2024 | 85,830.00 |